FXR

Fexarine is a potent, selective agonist of farnesoid X receptor.

ST-1892 is a soluble partial FXR agonist.

LY367385 is a highly effective and selective mGluR1a antagonist.

HPG1860, an agonist of the farnesoid X receptor (FXR), induces luminescence in reporter gene assays utilizing HEK293T cells expressing human FXR, with an EC50 value of 18 nM. In vivo studies demonstrate that HPG1860 (administered at 1, 3, or 10 mg/kg daily) reduces serum alanine aminotransferase (ALT) and total cholesterol levels in a mouse model of non-alcoholic steatohepatitis (NASH), which was induced by a high-fat diet and carbon tetrachloride (CCl4). Additionally, this compound decreases hepatic inflammation, fat levels, and fibrosis.

FXR agonist 4: EC50 of 1.05μM, treats hyperlipidemia, steatosis, insulin resistance, inflammation in DIO mice, for NAFLD research.

EDP-305, an oral FXR agonist, has EC50s of 34 nM/8 nM in CHO/HEK cells, aids in PBC and NASH research with antifibrotic properties.

BMS-986318: potent FXR agonist, EC50=53/350 nM, good ADME, effective in liver disease models, for nonalcoholic steatohepatitis research.

GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.

"Oral FXR antagonist 1 selectively blocks intestinal FXR, with IC50 of 2.1 μM, aiding in NASH research by improving liver health."

Chenodeoxycholic acid 24-acyl-β-D-glucuronide (CDCA-24G), a metabolite of CDCA, is synthesized from CDCA via the action of the UDP-glucuronosyltransferase (UG UT) isoform UGT1A3.

Chenodeoxycholic acid 3-glucuronide (CDCA-3G), a metabolite of Chenodeoxycholic acid (CDCA), is synthesized in human liver microsomes.

GSK-8062 is an agonist of farnesoid X receptor (FXR).

Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation.

Lecufexor is an agonist of the farnesoid X receptor (FXR).

BAR-2227 (compound 3a) functions as an FXR agonist and a LIFR inhibitor. It is utilized in the study of liver fibrosis and inflammation.

BMS-986339: oral, potent FXR agonist; binds to His298/ASN287; for PBC, PSC, NASH, anti-fibrosis research.

Danifexor is an agonist of the farnesoid X receptor (Farnesoid X receptor).

FXR agonist12 (Compound C7) is an orally active FXR agonist. It downregulates bile acid synthesis-related genes and upregulates bile acid transport-related genes in HepG2 cells. FXR agonist12 alleviates ANIT-induced cholestasis and reduces liver damage and fibrosis in a mouse model of NASH.

FXR agonist9 (compound 26) is a selective, orally active partial agonist of FXR with an EC50 of 0.09 µM (maximum efficacy of 75.13%). It ameliorates the pathological features of fatty liver disease in mice induced by HFD and CCl4-related metabolic dysfunction.